Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) fell 3% during mid-day trading on Thursday . The company traded as low as $417.50 and last traded at $428.08, with a volume of 1,123,488 shares trading hands. The stock had previously closed at $441.37.

A number of research firms recently issued reports on REGN. Leerink Swann reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, April 30th. Cowen and Company restated a “hold” rating and issued a $430.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday. Piper Jaffray Cos. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Sunday, May 8th. Wells Fargo & Co. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 8th. Finally, Citigroup Inc. restated a “buy” rating and issued a $470.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 23rd. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $491.71.

The firm’s 50-day moving average price is $379.75 and its 200-day moving average price is $390.79. The company has a market capitalization of $44.11 billion and a P/E ratio of 67.07.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.65 by $0.17. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.24 billion. The company’s revenue was up 21.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.89 earnings per share. On average, equities research analysts forecast that Regeneron Pharmaceuticals Inc. will post $10.90 earnings per share for the current year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of the business’s stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the completion of the transaction, the director now owns 15,125 shares in the company, valued at $6,428,125. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Ryan sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $396.64, for a total value of $396,640.00. Following the transaction, the director now owns 40,500 shares of the company’s stock, valued at approximately $16,063,920. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have made changes to their positions in the stock. Victory Capital Management Inc. raised its position in shares of Regeneron Pharmaceuticals by 106.2% in the fourth quarter. Victory Capital Management Inc. now owns 2,072 shares of the biopharmaceutical company’s stock valued at $1,125,000 after buying an additional 1,067 shares during the period. Stephens Inc. AR raised its position in shares of Regeneron Pharmaceuticals by 8.3% in the fourth quarter. Stephens Inc. AR now owns 2,488 shares of the biopharmaceutical company’s stock valued at $1,351,000 after buying an additional 190 shares during the period. Genesee Valley Trust Co. raised its position in shares of Regeneron Pharmaceuticals by 4.1% in the fourth quarter. Genesee Valley Trust Co. now owns 2,972 shares of the biopharmaceutical company’s stock valued at $1,613,000 after buying an additional 117 shares during the period. Suntrust Banks Inc. raised its position in shares of Regeneron Pharmaceuticals by 753.5% in the fourth quarter. Suntrust Banks Inc. now owns 3,832 shares of the biopharmaceutical company’s stock valued at $2,079,000 after buying an additional 3,383 shares during the period. Finally, US Bancorp DE raised its position in shares of Regeneron Pharmaceuticals by 9.4% in the fourth quarter. US Bancorp DE now owns 3,975 shares of the biopharmaceutical company’s stock valued at $2,158,000 after buying an additional 340 shares during the period.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.